SyntaraASX:SNT -9.52% Pretax Margin % is % as of Dec. 2025. The stock has 1 warning sign investors should review. Among 952 Drug Manufacturers companies, Syntara ranks worse than 105041.91% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Syntara's Pre-Tax Income for the
six
months ended in Dec. 2025 was A$-6.05 Mil. Syntara's Revenue for the
six
months ended in Dec. 2025 was A$0.00 Mil. Therefore, Syntara's pretax margin for the quarter that ended in Dec. 2025 was %.
The historical rank and industry rank for Syntara's Pretax Margin % or its related term are showing as below:
ASX:SNT's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.295 * Ranked among companies with meaningful Pretax Margin % only.
Syntara (ASX:SNT) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Syntara Pretax Margin % Related Terms
Syntara Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Syntara's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syntara Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syntara's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Syntara's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syntara (ASX:SNT) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Syntara and its competitors. According to the industry distribution chart, Syntara ranks #999999 out of 952 companies in the Drug Manufacturers industry.
Is Syntara's Pretax Margin % too high?
Syntara's current Pretax Margin % is %. Based on the distribution chart, Syntara ranks #999999 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Syntara's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Syntara ranks #999999 out of 952 companies for Pretax Margin %. This places Syntara in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Syntara and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syntara's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syntara stock overvalued right now?
Syntara (ASX:SNT) has a current Pretax Margin % of %. The current Pretax Margin % is %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Syntara (ASX:SNT), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring and neuroinflammation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SNT has been successfully added to your 